These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 23108522)

  • 41. Anticoagulation in the management of ST-segment elevation myocardial infarction.
    Dobesh PP; Trujillo TC
    J Pharm Pract; 2010 Aug; 23(4):335-43. PubMed ID: 21507833
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [New anticoagulants: better knowledge, better prescriptions].
    Boehlen F; de Moerloose P
    Rev Med Suisse; 2012 Jan; 8(324):96-9. PubMed ID: 23185817
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rivaroxaban for the treatment of acute coronary syndromes.
    Wong CK; White HD
    Expert Opin Pharmacother; 2013 May; 14(7):917-27. PubMed ID: 23544968
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rivaroxaban and risk of myocardial infarction: insights from a meta-analysis and trial sequential analysis of randomized clinical trials.
    Chatterjee S; Sharma A; Uchino K; Biondi-Zoccai G; Lichstein E; Mukherjee D
    Coron Artery Dis; 2013 Dec; 24(8):628-35. PubMed ID: 24145765
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [The ROCKET AF study].
    Capucci A; Prisco D
    G Ital Cardiol (Rome); 2012 Sep; 13(9):553-6. PubMed ID: 22825339
    [No Abstract]   [Full Text] [Related]  

  • 46. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control.
    Skanes AC; Healey JS; Cairns JA; Dorian P; Gillis AM; McMurtry MS; Mitchell LB; Verma A; Nattel S;
    Can J Cardiol; 2012; 28(2):125-36. PubMed ID: 22433576
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Secondary prevention of myocardial infarct. A new anticoagulant improves survival prospects].
    Einecke D
    MMW Fortschr Med; 2011 Dec; 153(48):14-5. PubMed ID: 22299243
    [No Abstract]   [Full Text] [Related]  

  • 48. Novel oral anticoagulation in management of venous thromboembolism, atrial fibrillation, and acute coronary syndrome.
    Khemasuwan D; Suramaethakul N
    Clin Appl Thromb Hemost; 2012 Sep; 18(5):476-86. PubMed ID: 22387584
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rivaroxaban in acute coronary syndromes: too soon to know?
    Gurm HS; Eagle K
    Lancet; 2009 Jul; 374(9683):3-4. PubMed ID: 19539362
    [No Abstract]   [Full Text] [Related]  

  • 50. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
    Dumont B; Faille D; Ajzenberg N
    Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A new era in secondary prevention after acute coronary syndrome.
    Roe MT; Ohman EM
    N Engl J Med; 2012 Jan; 366(1):85-7. PubMed ID: 22077849
    [No Abstract]   [Full Text] [Related]  

  • 52. Rivaroxaban (Xarelto)--a new oral anticoagulant.
    Med Lett Drugs Ther; 2011 Aug; 53(1371):65-7. PubMed ID: 21860366
    [No Abstract]   [Full Text] [Related]  

  • 53. A new generation of oral direct anticoagulants.
    Soff GA
    Arterioscler Thromb Vasc Biol; 2012 Mar; 32(3):569-74. PubMed ID: 22345595
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anticoagulation therapy and the risk of stroke in patients with atrial fibrillation at 'moderate risk' [CHADS2 score=1]: simplifying stroke risk assessment and thromboprophylaxis in real-life clinical practice.
    Lip GY
    Thromb Haemost; 2010 Apr; 103(4):683-5. PubMed ID: 20135056
    [No Abstract]   [Full Text] [Related]  

  • 55. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.
    ROCKET AF Study Investigators
    Am Heart J; 2010 Mar; 159(3):340-347.e1. PubMed ID: 20211293
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [New anticoagulants: dabigatran, rivaroxaban and apixaban].
    Vargas Ruiz AG; Ramírez López AN; Medina Viramontes ME
    Gac Med Mex; 2012; 148(3):257-64. PubMed ID: 22820359
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New anticoagulant agents in acute coronary syndromes.
    Höchtl T; Farhan S; Wojta J; Huber K
    Heart; 2011 Feb; 97(3):244-52. PubMed ID: 21189310
    [No Abstract]   [Full Text] [Related]  

  • 58. Warfarin Monotherapy in Atrial Fibrillation Patients With Stable Coronary Disease One Year After Myocardial Infarction/Stent: Two Birds With One Stone?
    Chou AY; Mancini GB
    Can J Cardiol; 2015 Aug; 31(8):1070-2. PubMed ID: 26111669
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Swedish powerhouse of clinical research.
    Shurlock B
    Eur Heart J; 2014 Feb; 35(5):261-2. PubMed ID: 24645187
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rivaroxaban in patients with a recent acute coronary syndrome event: integration of trial findings into clinical practice.
    Shivu GN; Ossei-Gerning N
    Vasc Health Risk Manag; 2014; 10():291-302. PubMed ID: 24868164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.